LON:AGY Allergy Therapeutics (AGY) Share Price, News & Analysis GBX 4.15 +0.15 (+3.75%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range 3.80▼ 4.1550-Day Range 3.88▼ 5.8052-Week Range 1.20▼ 6.30Volume468,008 shsAverage Volume814,773 shsMarket Capitalization£197.96 millionP/E RatioN/ADividend Yield8.33%Price TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Allergy Therapeutics alerts: Email Address Ad Porter & CompanyWhy billionaires are wiring money to abandoned towns A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video About Allergy Therapeutics Stock (LON:AGY)Allergy Therapeutics plc, a commercial biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Acarovac Plus, Pollinex, Synbiotics, and VLP Peanut. The company develops allergy vaccines for pollen, house dust mites, and animal fur, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.Read More AGY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AGY Stock News HeadlinesAugust 27, 2024 | lse.co.ukAllergy Therapeutics secures cash to see it through SeptemberMay 16, 2024 | msn.comFood Allergy Awareness Week 2024: How can new treatments target an unmet need?September 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.May 10, 2024 | markets.businessinsider.comBuy Rating Justified for Aquestive Therapeutics Amidst Innovative Allergy Treatment and Strong Financial ProspectsMay 9, 2024 | tmcnet.comGlobal Skin Allergy Testing Market Expected to Reach $771.5 Million by 2028May 2, 2024 | msn.comSkin patch improves treatment for pediatric milk allergiesApril 27, 2024 | businesswire.comGlobal Skin Allergy Testing Market Report 2024: Revenue Data for 2020-2022, Estimated Figures for 2023, and Forecasts for 2028 - ResearchAndMarkets.comApril 18, 2024 | dailymail.co.ukThe most common 'inhalant' allergiesSeptember 7, 2024 | Porter & Company (Ad)The death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.March 29, 2024 | finance.yahoo.comAllergy Therapeutics First Half 2024 Earnings: UK£0.006 loss per share (vs UK£0.013 loss in 1H 2023)March 28, 2024 | lse.co.ukAIM WINNERS & LOSERS: Norman Broadbent profit swing on rising revenueMarch 2, 2024 | finance.yahoo.comAllergy Therapeutics plc (AGY.L)November 8, 2023 | morningstar.comAllergy Therapeutics PLC AGYNovember 6, 2023 | marketwatch.comAllergy Therapeutics Extends Cash Runway to End of YearOctober 14, 2023 | finance.yahoo.comAllergy Therapeutics (LON:AGY) dips 10.0% this week as increasing losses might not be inspiring confidence among its investorsOctober 13, 2023 | marketwatch.comAllergy Therapeutics to Raise GBP40.75 Mln; Mandatory Cash Offer TriggeredJuly 31, 2023 | abcnews.go.comRed meat allergy caused by ticks is an 'emerging public health concern': CDCJune 22, 2023 | forbes.comWhat Is A Mold Allergy? Symptoms, Causes And TreatmentsSee More Headlines Receive AGY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergy Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/04/2020Today9/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:AGY CUSIPN/A CIKN/A Webwww.allergytherapeutics.com Phone+44-1903-844700FaxN/AEmployees612Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth-30.7Net Income£-50,220,000.00 Net Margins-94.29% Pretax MarginN/A Return on Equity-155.90% Return on Assets-34.76% Debt Debt-to-Equity Ratio37.22 Current Ratio1.40 Quick Ratio1.48 Sales & Book Value Annual Sales£53.26 million Price / Sales3.72 Cash FlowGBX 1.14 per share Price / Cash Flow3.66 Book ValueGBX 1 per share Price / Book4.15Miscellaneous Outstanding Shares4,770,000,000Free FloatN/AMarket Cap£197.96 million OptionableNot Optionable Beta1.45 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesMr. Manuel Llobet (Age 59)CEO & Executive Director Comp: $411.98kMr. Shaun Antony Furlong (Age 48)CFO & Executive Director Ms. Beverly LeesGroup Operations DirectorDr. Murray SkinnerChief Scientific OfficerMr. Santiago PuigBusiness Development DirectorMs. Sue BakerHead of Human ResourcesSimon PiggottHead of Clinical ScienceAlan BullimoreHead of Communication & Market DevelopmentMr. Russell PicketGroup Financial ControllerKarley Charlotte Mouatt CheesmanCompany SecretaryMore ExecutivesKey CompetitorsAmryt PharmaLON:AMYTBenchmarkLON:BMKAlliance PharmaLON:APHAnimalcare GroupLON:ANCRBeximco PharmaceuticalsLON:BXPView All CompetitorsInsidersZheqing ShenBought 247,935,056 shares on 11/9/2023Total: £247.94 M ($1.00/share) AGY Stock Analysis - Frequently Asked Questions How have AGY shares performed this year? Allergy Therapeutics' stock was trading at GBX 2.50 at the beginning of 2024. Since then, AGY shares have increased by 66.0% and is now trading at GBX 4.15. View the best growth stocks for 2024 here. How were Allergy Therapeutics' earnings last quarter? Allergy Therapeutics plc (LON:AGY) announced its quarterly earnings results on Wednesday, March, 4th. The company reported $2.40 earnings per share for the quarter. Allergy Therapeutics had a negative net margin of 94.29% and a negative trailing twelve-month return on equity of 155.90%. How do I buy shares of Allergy Therapeutics? Shares of AGY stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What other stocks do shareholders of Allergy Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allergy Therapeutics investors own include (RLYP) (RLYP), Royalty Pharma (RPRX), Verastem (VSTM), Berkeley Energia (BKY), Burford Capital (BUR) and Direxion Daily Gold Miners Index Bear 2x Shares (DUST). This page (LON:AGY) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergy Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergy Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.